BDBM582030 Preparation of (2S,4R)-1-((S)-2-(5-(4-(((E)-4-(6-chloro-2-methyl-2H-indazol-5-yl)idene amino)-2,6-dioxy-3-(2,4,5-trifluorobenzyl)-1,3,5-triazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)pentanamido)-3,3-dimethylbutyryl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide::US11518759, Compound 3
SMILES Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCn2cc(Cn3c(=O)[nH]\c(=N/c4cc5cn(C)nc5cc4Cl)n(Cc4cc(F)c(F)cc4F)c3=O)nn2)C(C)(C)C)cc1
InChI Key InChIKey=XQMHVNNMDDXAFN-WXQABQIWSA-N
Data 1 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 1 hit for monomerid = 582030
TargetReplicase polyprotein 1a(Human SARS coronavirus (SARS-CoV))
Shaanxi Panlong Pharmaceutical
US Patent
Shaanxi Panlong Pharmaceutical
US Patent
Affinity DataIC50: 550nMAssay Description:The inhibitory activity of the compounds against SARS-CoV-2 3CLpro was determined using fluorescence resonance energy transfer.10 μL of the comp...More data for this Ligand-Target Pair